Could a diabetes drug help young adults with rare obesity conditions lose weight?

NCT ID NCT06901245

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times

Summary

This study is testing a weight-loss medication called tirzepatide in young adults aged 18-26 who have obesity due to Prader-Willi syndrome, hypothalamic obesity, or general causes. Participants will take the drug for one year to see how much weight they lose and how their health changes. The goal is to find out if the drug works as well in people with these specific conditions as it does in those with common obesity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRADER-WILLI SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Minnesota

    RECRUITING

    Saint Paul, Minnesota, 55102, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Seattle Children's Hospital

    RECRUITING

    Seattle, Washington, 98105, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.